Erastin

Catalog No.S7242 Batch:S724204

Print

Technical Data

Formula

C30H31ClN4O4
Molecular Weight 547.04 CAS No. 571203-78-6
Solubility (25°C)* In vitro DMSO (warmed with 60ºC water bath) 25 mg/mL (45.7 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
10%DMSO 40%PEG300 5%Tween80 45%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 1.670mg/ml (3.05mM) Taking the 1 mL working solution as an example, add 100 μL of 16.67 mg/ml clear DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to make it clear. Volume up to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions are unstable and should be fresh-prepared.
Targets
Ferroptosis [1]
In vitro

Erastin is selectively lethal to oncogenic RAS-mutant cell lines, and triggers a unique iron-dependent form of non-apoptotic cell death called ferroptosis.

This compound binds directly to VDAC2 and causes mitochondrial damage via ROS production in an NADH-dependent manner, which induces cell death in some tumor cells harbouring activating mutations in the RAS-RAF-MEK pathway.

In addition, this chemical, via inducing ROS-mediated CID (Caspase-independent cell death), strongly enhances the effect in WT EGFR cells.

In vivo

Erastin is a ferroptosis activator by inhibiting voltage-dependent anion channels (VDAC2/VDAC3). This compound also inhibits cystine-glutamate antiporter (xCT).

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    BJ-TERT/LT/ST/RASV12 cells

  • Concentrations

    5 or 10 μg/mL

  • Incubation Time

    6-11 hours

  • Method

    BJ-TERT/LT/ST/RASV12 cells are seeded in 100 mm dishes and allowed to grow overnight. Cells are treated with erastin (5 or 10 μg/ml) for 6, 8, or 11 hr. A camptothecin-treated (0.4 μg/ml) control is maintained, treated at the time of seeding for 20 hours. After the treatment, cells are harvested with trypsin/EDTA and washed once with fresh medium containing serum and then twice with phosphate-buffered saline. Cells are resuspended in 1× binding buffer. 100 μL is incubated with 5 μL of Annexin V-FITC and propidium iodiode for 15 min in the dark at room temperature. Then 400 μl of the 1× binding buffer s added and the cells analyzed by flow cytometry. Data are acquired and analyzed using Cellquest software. Only viable cells that do not stain with propidium iodiode are analzyed for Annexin V-FITC staining using the FL1 channel.
Animal Study:

[5]

 
  • Animal Models

    C57BL/6 mice

  • Dosages

    10 mg/kg

  • Administration

    i.n.

References

  • https://pubmed.ncbi.nlm.nih.gov/12676586/
  • https://pubmed.ncbi.nlm.nih.gov/22632970/
  • https://pubmed.ncbi.nlm.nih.gov/17568748/
  • https://pubmed.ncbi.nlm.nih.gov/23344263/
  • https://pubmed.ncbi.nlm.nih.gov/35197442/

Customer Product Validation

<p>Western blot analysis indicated protein expression in PDAC cells following treatment with erastin (2.5-40 μmol/L) for 24 hours (n=3, * P < 0.05 vs. untreated group)</p>

, , Cancer Res, 2017, 77(8):2064-2077

PANC1 and PANC2.03 cells were treated with staurosporine or erastin (D) in the absence or presence of indicated cell death inhibitors for 24 hours. Cell viability was assayed (n = 3, *P < 0.05).

Data from [ , , Gastroenterology, 2017, 153(5):1429-1443 ]

PANC1 cells were treated with JTC801 (10 μM), erastin (20 μM) in the absence or presence of ferrostatin-1 (500 nM) for 24 hours. Cell viability was assayed (n=3, **p < 0.01, ***p < 0.001, n.s.=not significant).

Data from [ , , Gastroenterology, 2018, 154(5):1480-1493 ]

Indicated HCC cells were treated with sorafenib (5 μM) and erastin (10 μM) with or without cell death inhibitors (ferrostatin-1, 1 μM; liprostatin-1, 100 nM; ZVAD-FMK, 10 μM; necrosulfonamide, 0.5 μM) for 24 hours, and cell viability was assayed (n=3, *P < 0.05 versus sorafenib or erastin treatment group).

Data from [ , , Hepatology, 2016, 64(2):488-500. ]

Selleck's Erastin Has Been Cited by 554 Publications

The ferroptosis inducer erastin promotes proliferation and differentiation in human peripheral blood mononuclear cells [ Biochemical and Biophysical Research Communications, September 10, 2018, 1689-1695] PubMed: 30049441
Erastin Disrupts Mitochondrial Permeability Transition Pore (mPTP) and Induces Apoptotic Death of Colorectal Cancer Cells [ PLoS One, May 12, 2016, e0154605] PubMed: 27171435
Erastin triggers autophagic death of breast cancer cells by increasing intracellular iron levels [ Oncology Letters, July 29, 2020, 57] PubMed: 32793311
Strong Protection by 4-Hydroxyestrone against Erastin-Induced Ferroptotic Cell Death in Estrogen Receptor-Negative Human Breast Cancer Cells: Evidence for Protein Disulfide Isomerase as a Mechanistic Target for Protection [ Biochemistry, April 3, 2024, 984-999] PubMed: 38569593
Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy [ Nat Cell Biol, 2026, 28(4):783-796] PubMed: 41813885
mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway [ Mol Cell, 2026, 86(8):1546-1559.e8] PubMed: 41997112
The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer [ Mol Cell, 2026, 86(7):1260-1274.e4] PubMed: 41932308
Ferroptosis-related mechanisms in prion diseases provide insights into neurodegeneration and reveal therapeutic implications [ Redox Biol, 2026, 93:104155] PubMed: 41945998
Peroxisome-derived and liver-specific hydroxyacid oxidase 1-mediated hydrogen peroxide promotes ferroptosis by augmenting peroxisomal ROS [ J Adv Res, 2026, S2090-1232(26)00342-5] PubMed: 41990971
FAK/SRC-JNK axis promotes ferroptosis via upregulating ACSL4 expression [ Cell Death Dis, 2026, 17(1)328] PubMed: 41862445

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.